With at least five antibody generation companies available to serve drug developers, it seems unnecessary for a company interested in antibodies to acquire its own generation capability. But Alexion Pharmaceuticals Inc. determined that its need for antibodies against internally identified targets is great enough that it made more sense economically to bring such technology in house, leading to last week's deal to acquire antibody phage display company Proliferon Inc.

"It comes down to